Lamzede

Velmanase alfa, the active ingredient in Lamzede, is a recombinant enzyme presented as an intravenous solution for intravenous use. It is used to treat alpha‑mannosidosis, a rare lysosomal storage disorder, in patients requiring enzyme replacement therapy.

GNH USA supplies Lamzede as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Lamzede provides enzyme replacement for the lysosomal pathway affected in alpha‑mannosidosis.

- Alpha‑mannosidosis: replaces deficient alpha‑mannosidase to support lysosomal degradation of mannose‑rich oligosaccharides. - Lysosomal storage disease management: helps reduce accumulation of mannose‑rich substrates in cells. - Metabolic disorder therapy: may improve clinical signs associated with the underlying enzyme deficiency.

Common Side Effects: - Infusion‑related reactions (e.g., flushing, chills) - Fever or chills - Headache - Nausea - Vomiting - Mild hypotension

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity - Serum sickness‑like reactions - Severe hypotension or shock - Pulmonary edema - Acute respiratory distress - Life‑threatening allergic reactions

Lamzede should be administered under medical supervision with appropriate monitoring.

- Monitor infusion reactions: observe patients for signs of hypersensitivity during and after infusion. - Assess liver function: periodic liver enzyme testing is recommended. - Evaluate for hypersensitivity: avoid use in patients with known severe allergy to the product. - Consider immunogenicity: patients may develop antibodies that affect efficacy. - Avoid in patients with uncontrolled severe infection. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Lamzede may interact with other biologic agents and vaccines.

Major Interactions (Avoid): - Live vaccines: concurrent administration may increase risk of infection. - Other enzyme replacement therapies: may compound immune response.

Moderate Interactions (Monitor Closely): - Immunosuppressants: may alter efficacy or increase infection risk. - Anticoagulants: infusion may affect bleeding parameters; monitor coagulation status. - Concomitant biologics: monitor for enhanced immune reactions. - High‑dose steroids: may mask infusion‑related symptoms; observe closely.